ArticleBMC cancer2026

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Jaume Capdevila et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.